Related Experiment Videos
Luciferins behave like drugs.
David M Mofford1, Stephen C Miller1
1Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.
ACS Chemical Neuroscience
|July 31, 2015
Summary
Bioluminescent imaging uses firefly luciferase to visualize brain processes. New probes targeting fatty acid amide hydrolase (FAAH) may overcome blood-brain barrier limitations for enhanced sensitivity in brain imaging.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Imaging
Background:
- Firefly luciferase bioluminescence enables visualization of biological processes in live animals.
- Current methods using D-luciferin face limitations due to the blood-brain barrier, affecting sensitivity and interpretation.
- Optical imaging in the brain requires strategies to overcome biological barriers.
Purpose of the Study:
- To discuss novel bioluminescent imaging probes for fatty acid amide hydrolase (FAAH).
- To explore the implications of these probes for optical imaging in the brain.
- To consider the potential for improved drug delivery strategies.
Main Methods:
- Review of current bioluminescent imaging techniques.
- Discussion of challenges associated with blood-brain barrier penetration.
- Exploration of enzyme-specific probe development for brain imaging.
Main Results:
- Development of bioluminescent probes targeting FAAH offers a potential solution to blood-brain barrier limitations.
- These probes could enhance sensitivity and allow for more accurate interpretation of brain imaging experiments.
- The approach has broader implications for in vivo optical imaging and therapeutic delivery.
Conclusions:
- Targeting FAAH with bioluminescent probes represents a promising advancement for brain imaging.
- Overcoming the blood-brain barrier is crucial for sensitive and reliable optical imaging of neural activity.
- This strategy may pave the way for new diagnostic and therapeutic applications in neuroscience.